Home LiteratureArticle Details
PMID: 1899349 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.

BMJ (Clinical research ed.) ·Vol. 302 ·No. 6767 ·1991-01-05 ·Pages 23-6

Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J

Abstract

To study the contribution of the humoral response to HIV-I at seroconversion to disease outcome after 84 months. A retrospective longitudinal study. Two haemophilia centres in the United Kingdom. 88 Haemophiliac patients infected with HIV-I for whom sera were available from before seroconversion and in whom clinical follow up data were available. Kaplan-Meier survival analysis showed a significant difference between a high titre (greater than 1600) p24 antibody response at seroconversion and prolonged time before the development of HIV related disease (p = 0.0008). In contrast, higher titres of antibody to gp120 at seroconversion (greater than 25,600) correlated with more rapid clinical deterioration (p = 0.025). The first humoral response to HIV proteins at seroconversion is associated with clinical outcome; patients with an initial low titre antibody response to the gagp24 protein have a significantly faster rate of progression to CDC stage IV disease. Patients with a high titre p24 antibody response progress to AIDS more slowly, and these data provide an explanation why p24 antigenaemia is not universally detected in patients with AIDS. It is unclear whether the association between a strong initial p24 antibody response and slower progression of HIV disease is causal and if so whether it is due to viral or host factors.

MeSH Terms
Gene Products, gag/immunology Gene Products, nef/immunology HIV Antibodies/biosynthesis HIV Antigens/immunology HIV Core Protein p24 HIV Envelope Protein gp120/immunology HIV Infections/mortality HIV Seropositivity/immunology,mortality HIV-1/immunology Hemophilia A/immunology Humans Longitudinal Studies Retrospective Studies Survival Analysis Viral Core Proteins/immunology nef Gene Products, Human Immunodeficiency Virus
Chemicals
Gene Products, gag Gene Products, nef HIV Antibodies HIV Antigens HIV Core Protein p24 HIV Envelope Protein gp120 Viral Core Proteins nef Gene Products, Human Immunodeficiency Virus
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Cheingsong-Popov R
Department of Medicine, Royal Postgraduate Medical School, London.
Panagiotidi C
Bowcock S
Aronstam A
Wadsworth J
Weber J
References (37)
37 references, click to expand
  1. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis.
    Lancet. 1987 Jan 17;1(8525):119-22 PMID: 2879968
  2. Antibody response in primary human immunodeficiency virus infection.
    Lancet. 1987 May 30;1(8544):1249-53 PMID: 2884379
  3. Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS.
    N Engl J Med. 1985 Jan 31;312(5):265-70 PMID: 2981407
  4. Variation in human T lymphotropic virus III (HTLV-III) antibodies in homosexual men: decline before onset of illness related to acquired immune deficiency syndrome (AIDS).
    Br Med J (Clin Res Ed). 1985 Oct 12;291(6501):997-8 PMID: 2996691
  5. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees.
    Proc Natl Acad Sci U S A. 1989 Jun;86(12):4710-4 PMID: 2471977
  6. Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs.
    Lancet. 1986 Nov 29;2(8518):1233-6 PMID: 2878129
  7. Patterns of antibody response in individuals infected with the human immunodeficiency virus.
    J Infect Dis. 1987 Apr;155(4):626-32 PMID: 3546516
  8. HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohort.
    Br Med J (Clin Res Ed). 1988 Feb 27;296(6622):593-8 PMID: 3126920
  9. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease.
    Lancet. 1988 May 28;1(8596):1185-8 PMID: 2897006
  10. Antibodies to HIV-1 nef(p27): prevalence, significance, and relationship to seroconversion.
    AIDS Res Hum Retroviruses. 1990 Sep;6(9):1099-105 PMID: 2265027
  11. Detection of IgG antibodies to lymphadenopathy-associated virus in patients with AIDS or lymphadenopathy syndrome.
    Lancet. 1984 Jun 9;1(8389):1253-6 PMID: 6144973
  12. Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain.
    Lancet. 1984 Sep 1;2(8401):477-80 PMID: 6147546
  13. Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS.
    Science. 1984 May 4;224(4648):503-5 PMID: 6200937
  14. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.
    Science. 1984 May 4;224(4648):506-8 PMID: 6324345
  15. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study.
    Lancet. 1990 Apr 21;335(8695):927-30 PMID: 1970024
  16. HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4.
    Lancet. 1990 Apr 7;335(8693):811-5 PMID: 1690832
  17. Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus.
    Clin Immunol Immunopathol. 1986 Sep;40(3):515-24 PMID: 3731542
  18. Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progression.
    J Clin Invest. 1987 Aug;80(2):316-24 PMID: 3497176
  19. Antibody response to human immunodeficiency virus after primary infection.
    J Infect Dis. 1987 Jun;155(6):1113-8 PMID: 3553344
  20. Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection.
    Lancet. 1987 Sep 12;2(8559):589-93 PMID: 2887886
  21. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.
    N Engl J Med. 1989 Dec 14;321(24):1621-5 PMID: 2586564
  22. Plasma viremia in human immunodeficiency virus infection.
    N Engl J Med. 1989 Dec 14;321(24):1626-31 PMID: 2511447
  23. Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation.
    Science. 1989 Sep 22;245(4924):1380-2 PMID: 2571187
  24. Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30.
    Proc Natl Acad Sci U S A. 1987 May;84(9):2951-5 PMID: 2437588
  25. Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.
    J Virol. 1989 Jan;63(1):267-72 PMID: 2462060
  26. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.
    Br Med J (Clin Res Ed). 1986 Dec 6;293(6560):1459-62 PMID: 3099912
  27. Viral gene expression, antibody production and immune complex formation in human immunodeficiency virus infection.
    AIDS. 1987 May;1(1):15-20 PMID: 3122785
  28. Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection.
    Br Med J (Clin Res Ed). 1987 Sep 5;295(6598):567-9 PMID: 3117234
  29. Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus.
    Br Med J (Clin Res Ed). 1986 Jan 25;292(6515):228-30 PMID: 3004634
  30. Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria.
    Virology. 1986 Apr 15;150(1):283-90 PMID: 3006341
  31. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry.
    Science. 1988 Oct 28;242(4878):580-3 PMID: 2972065
  32. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion.
    Cell. 1988 Aug 12;54(4):561-75 PMID: 2969774
  33. Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.
    Science. 1985 May 31;228(4703):1094-6 PMID: 2986291
  34. Restriction of sensitivity of HIV-1-antigen ELISA by serum anti-core antibodies.
    AIDS. 1988 Feb;2(1):41-5 PMID: 3128995
  35. Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection.
    AIDS. 1987 Dec;1(4):235-40 PMID: 3126771
  36. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.
    Br Med J (Clin Res Ed). 1988 Mar 12;296(6624):745-50 PMID: 3126959
  37. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia.
    Br Med J (Clin Res Ed). 1987 Sep 5;295(6598):569-72 PMID: 3117235
Article Info
Journal
BMJ (Clinical research ed.)
Abbr.
BMJ
ISSN
0959-8138
DOI
10.1136/bmj.302.6767.23
Published
1991-01-05
Pages
23-6
Language
English
Region
England
NLM ID
8900488
PMCID
PMC1668741
Subset
IM
External Links
PubMed source DOI: 10.1136/bmj.302.6767.23 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2